Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Фаза 2 Идёт, набор закрыт NCT02883062

Кратко

This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Change in Tumor Infiltrating Lymphocyte (TIL) Percentage

Baseline and between days 18-22 following completion of cycle 1 (each cycle is 3 weeks) · percentage of TIL

Pathologic Complete Response (pCR) Rate

At the time of surgery (3-6 weeks after last dose of neoadjuvant chemotherapy, neoadjuvant chemotherapy will be up to 12 weeks in length) · Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• Vitamin D and Physical Activity on Bone Health — University of Rochester
• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in T — National Cancer Institute (NCI)
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Can — AstraZeneca
• Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Adm — University of Colorado, Denver

Все исследования